Gordon S M, Eaton M E, George R, Larsen S, Lukehart S A, Kuypers J, Marra C M, Thompson S
Department of Medicine, Grady Memorial Hospital, Emory University School of Medicine, Atlanta.
N Engl J Med. 1994 Dec 1;331(22):1469-73. doi: 10.1056/NEJM199412013312201.
Infection with the human immunodeficiency virus (HIV) may affect both the natural course of syphilis and the response to treatment. We examined the response to treatment with high-dose penicillin G in HIV-infected patients with symptomatic neurosyphilis.
Neurosyphilis was defined by reactivity in serum treponemal tests for syphilis, neurologic manifestations consistent with neurosyphilis, and a positive Venereal Disease Research Laboratory (VDRL) test on cerebrospinal fluid. We identified 11 HIV-infected patients with symptomatic neurosyphilis; 5 had been treated previously for early syphilis with penicillin G benzathine. Patients were treated with 18 million to 24 million units of penicillin G per day administered intravenously for 10 days. Cerebrospinal fluid was examined approximately 6 and 24 weeks after treatment, when the polymerase chain reaction and rabbit inoculation were used to detect Treponema pallidum.
In four of the seven patients studied 24 weeks after treatment, the serum titers on rapid plasma reagin (RPR) testing decreased by at least two doubling dilutions, and four patients had reductions in the cerebrospinal fluid titers on VDRL testing or reverted to nonreactive results. In two patients there was no normalization or improvement in serum titers on RPR testing or cerebrospinal fluid titers on VDRL testing, cell counts, or protein concentrations. One patient relapsed with meningovascular syphilis six months after therapy. T. pallidum was detected by the polymerase chain reaction in cerebrospinal fluid from 3 of 10 patients before treatment, but in none of the 10 post-treatment specimens.
In patients with early syphilis who are also infected with HIV, therapy with penicillin G benzathine may fail, and neurosyphilis may develop. The regimen of high-dose penicillin recommended for neurosyphilis is not consistently effective in patients infected with HIV.
感染人类免疫缺陷病毒(HIV)可能会影响梅毒的自然病程以及对治疗的反应。我们研究了有症状神经梅毒的HIV感染患者对大剂量青霉素G治疗的反应。
神经梅毒的定义为梅毒血清梅毒螺旋体检测呈阳性反应、符合神经梅毒的神经系统表现以及脑脊液性病研究实验室(VDRL)试验呈阳性。我们确定了11例有症状神经梅毒的HIV感染患者;其中5例先前曾用苄星青霉素G治疗早期梅毒。患者每天静脉注射1800万至2400万单位青霉素G,持续10天。在治疗后约6周和24周检查脑脊液,此时采用聚合酶链反应和兔接种法检测梅毒螺旋体。
在治疗后24周研究的7例患者中,有4例快速血浆反应素(RPR)检测的血清滴度至少降低了两个稀释度倍数,4例患者VDRL检测的脑脊液滴度降低或转为阴性结果。2例患者的RPR检测血清滴度、VDRL检测脑脊液滴度、细胞计数或蛋白质浓度未恢复正常或改善。1例患者在治疗后6个月复发为脑膜血管梅毒。治疗前10例患者中有3例脑脊液通过聚合酶链反应检测到梅毒螺旋体,但治疗后的10份标本中均未检测到。
在同时感染HIV的早期梅毒患者中,苄星青霉素G治疗可能失败,且可能发生神经梅毒。推荐用于神经梅毒的大剂量青霉素方案对HIV感染患者并非始终有效。